GLP-1semaglutideglp-1 receptor agonistscardiovascular outcomesselect trial

Review estimates 35-55% of GLP-1 cardiovascular benefit is weight-loss independent

The Peptides paper synthesizes LEADER, SUSTAIN-6 and SELECT subgroup data alongside proposed endothelial and anti-inflammatory mechanisms.

By Maren Holt · Senior Reporter, GLP-1

Sep 22 20:00 ETSource: Peptides

The wire

01A review in Peptides reports that exploratory mediation analyses of major cardiovascular outcome trials suggest 35% to 55% of GLP-1 receptor agonist MACE reduction is not explained by weight loss.
02Supports prescribing GLP-1RAs for cardiovascular risk across BMI subgroups rather than treating benefit as purely a weight-loss effect.
03The authors caution the mediation estimates depend on model assumptions and do not establish causation; direct myocardial protection remains disputed in humans.

From the source

Advances in Weight-Loss-Independent Cardiovascular Protective Mechanisms of GLP-1 Receptor Agonists
Peptides · 2026 Sep 23 · Ma J, Feng X, Xu W et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42778024/